We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...

Merck reported positive results for its experimental treatment designed to protect infants from RSV. The mid to late-stage ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Merck is immune from an antitrust lawsuit accusing it of misleading regulators about the effectiveness of its mumps vaccine ...

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...

Merck & Co. hopes a new positive trial readout can return Keytruda to glory in head and neck cancer. | Merck & Co. hopes a ...

The latest trading day saw Merck (MRK) settling at $111.53, representing a +1.68% change from its previous close.

Merck’s STRIDE-8 phase 3 trial of Capvaxive demonstrates positive immune responses in adults with increased risk for pneumococcal disease: Rahway, New Jersey Thursday, October 1 ...

Alameda, California Tuesday, October 15, 2024, 14:00 Hrs [IST] ...

Keytruda (pembrolizumab) and Astellas/Pfizer’s Padcev (enfortumab vedotin) have been approved by the Medicines and Healthcare ...

“Merck has a strong heritage in oncology and our focus is bringing more medicines to patients with high unmet medical needs to improve and prolong lives. We believe those living with cancer deserve ...